Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Spark Restores Vision In Phase III; CEO Hopes To Lead Gene Therapy Field

This article was originally published in Scrip

Executive Summary

Spark Therapeutics is preparing to seek the first-ever US FDA approval for a gene therapy after several people who couldn't read a menu in a dimly lit restaurant or take a walk alone at dusk had their vision restored in a Phase III clinical trial testing SPK-RPE65.


Related Content

Spark Therapeutics Now Targets 2017 For US Approval Of First Retinal Gene Therapy